People · Operator

Dr. Jiang He

Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology

1
Companies
1
Filings
$295.1M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Vizgen, Inc.BiotechnologySeries D+$295.1M$320.2M2019
Operator network

Dr. Jiang He at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Keith Crandell · 11 companies · 1 sharedKeith CrandellAndrea Jackson · 6 companies · 1 sharedAndrea JacksonDavid Walt · 6 companies · 1 sharedDavid WaltMatthew Posard · 4 companies · 1 sharedMatthew PosardRobert Carson · 3 companies · 1 sharedRobert CarsonMarijn E. Dekkers · 2 companies · 1 sharedMarijn E. DekkersPhilip Gardella · 2 companies · 1 sharedPhilip GardellaChris Guiffre · 1 companies · 1 sharedChris GuiffreChristian Uhrich · 1 companies · 1 sharedChristian UhrichChristian Urhich · 1 companies · 1 sharedChristian UrhichDr. Peidong Wang · 1 companies · 1 sharedDr. Peidong WangDr. Philip Gardella · 1 companies · 1 sharedDr. Philip Gardel…Matthew E. Posard · 1 companies · 1 sharedMatthew E. PosardSeth Benson · 1 companies · 1 sharedSeth BensonSimona Levi · 1 companies · 1 sharedSimona LeviTerry Lo · 1 companies · 1 sharedTerry LoVizgen, Inc. · $295.1M raisedVizgen, Inc.Dr. Jiang HeDH
Dr. Jiang He Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Dr. Jiang He on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Keith Crandell111
Andrea Jackson16
David Walt16
Matthew Posard14
Robert Carson13
Philip Gardella12
Marijn E. Dekkers12
Matthew E. Posard11
Dr. Peidong Wang11
Dr. Philip Gardella11
Simona Levi11
Christian Uhrich11
Christian Urhich11
Chris Guiffre11
Terry Lo11
Seth Benson11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.